AML
Clinical trials for AML explained in plain language.
Never miss a new study
Get alerted when new AML trials appear
Sign up with your email to follow new studies for AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New precision therapy aims to intercept AML relapse before it starts
Disease control OngoingThis study tests whether giving targeted treatments based on a person's specific genetic mutations can prevent early relapse in acute myeloid leukemia (AML). It is designed for patients whose cancer shows signs of returning at a molecular level. The approach uses a platform trial…
Matched conditions: AML
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 09:36 UTC
-
New drug combo shows promise for Tough-to-Treat leukemia
Disease control OngoingThis study tests a new two-drug combination for adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to initial treatment. The drugs target a genetic change (FLT3 mutation) found in some AML patients. The goal is to see if the combinatio…
Matched conditions: AML
Phase: PHASE2 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated May 26, 2026 09:34 UTC
-
New antibody drug targets hidden cancer cells in blood cancers
Disease control OngoingThis study tests an experimental drug called vibecotamab in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) whose cancer did not fully respond to standard treatments. The drug works by helping the immune system find and destroy cancer cells that carry a…
Matched conditions: AML
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New chemo cocktail aims to boost remission in elderly AML patients
Disease control OngoingThis study compares two chemotherapy regimens for adults aged 60-75 with acute myeloid leukemia (AML) who can handle intensive treatment. The goal is to see if a new combination (HAV) works better than the standard DAV/IAV regimen at improving remission and survival. About 41 par…
Matched conditions: AML
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 18, 2026 12:02 UTC
-
New combo tackles blood cancer relapse after transplant
Disease control OngoingThis study tests a combination of two drugs (venetoclax and azacitidine) plus donor immune cells in people whose MDS or AML came back after a stem cell transplant. The goal is to find the best dose and see if the treatment can control the cancer. About 55 adults with relapsed dis…
Matched conditions: AML
Phase: PHASE1, PHASE2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated May 07, 2026 18:39 UTC